Sintilimab (a human anti-PD1 mAb) has been approved for second-line systemic treatment in lymphoma by the National Medical Products Administration of China, and it has demonstrated advantages in treating NSCLC [ORIENT-11 (40)]. This evidence concerns the gene RPL17 and lymphoma.